DAITO PHARMACEUTICAL CO.,LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,502 JPY | +0.08% |
|
+0.20% | +31.34% |
| Apr. 12 | Daito Pharmaceutical Co.,Ltd. announces an Equity Buyback for 350,000 shares, representing 2.23% for ¥1,000 million. | CI |
| Apr. 12 | Daito Pharmaceutical Co.,Ltd. authorizes a Buyback Plan. | CI |
Valuation
| Fiscal Period: May | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 42,109 | 56,950 | 44,980 | 37,154 | 33,086 | 38,563 | - | - |
| Enterprise Value (EV) 1 | 45,244 | 56,964 | 44,990 | 36,209 | 34,368 | 42,545 | 43,118 | 42,982 |
| P/E ratio | 12 x | 14.1 x | 10.5 x | 7.8 x | 9.2 x | 11.8 x | 10 x | 8.91 x |
| Yield | 1.13% | 1.06% | 1.4% | 2.29% | 2.61% | 2.4% | 2.64% | 2.9% |
| Capitalization / Revenue | 1.02 x | 1.27 x | 0.92 x | 0.85 x | 0.73 x | 0.81 x | 0.74 x | 0.69 x |
| EV / Revenue | 1.1 x | 1.27 x | 0.92 x | 0.83 x | 0.76 x | 0.89 x | 0.83 x | 0.77 x |
| EV / EBITDA | 6.11 x | 6.86 x | 4.96 x | 3.67 x | 3.79 x | 5.19 x | 4.2 x | 3.95 x |
| EV / FCF | 13.9 x | 36.2 x | -39.6 x | - | -83.4 x | -36 x | 8.29 x | 7.26 x |
| FCF Yield | 7.2% | 2.77% | -2.52% | - | -1.2% | -2.78% | 12.1% | 13.8% |
| Price to Book | 1.36 x | 1.57 x | 1.08 x | 0.79 x | 0.65 x | 0.74 x | 0.67 x | 0.62 x |
| Nbr of stocks (in thousands) | 13,765 | 14,368 | 15,085 | 15,617 | 15,803 | 15,413 | - | - |
| Reference price 2 | 3,059 | 3,964 | 2,982 | 2,379 | 2,094 | 2,502 | 2,502 | 2,502 |
| Announcement Date | 7/12/19 | 7/10/20 | 7/14/21 | 7/14/22 | 7/14/23 | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Mei | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 41,134 | 44,991 | 48,714 | 43,464 | 45,101 | 47,600 | 52,150 | 56,150 |
| EBITDA 1 | 7,400 | 8,307 | 9,063 | 9,866 | 9,077 | 8,200 | 10,275 | 10,875 |
| EBIT 1 | 4,547 | 5,357 | 5,908 | 6,553 | 5,207 | 4,775 | 5,575 | 6,275 |
| Operating Margin | 11.05% | 11.91% | 12.13% | 15.08% | 11.55% | 10.03% | 10.69% | 11.18% |
| Earnings before Tax (EBT) 1 | 4,618 | 5,595 | 5,873 | 6,720 | 5,076 | 4,755 | 5,580 | 6,280 |
| Net income 1 | 3,513 | 3,944 | 4,246 | 4,668 | 3,600 | 3,340 | 3,925 | 4,415 |
| Net margin | 8.54% | 8.77% | 8.72% | 10.74% | 7.98% | 7.02% | 7.53% | 7.86% |
| EPS 2 | 255.2 | 281.5 | 282.7 | 304.9 | 227.6 | 212.3 | 249.6 | 280.8 |
| Free Cash Flow 1 | 3,258 | 1,575 | -1,136 | - | -412 | -1,183 | 5,200 | 5,920 |
| FCF margin | 7.92% | 3.5% | -2.33% | - | -0.91% | -2.49% | 9.97% | 10.54% |
| FCF Conversion (EBITDA) | 44.03% | 18.96% | - | - | - | - | 50.61% | 54.44% |
| FCF Conversion (Net income) | 92.74% | 39.94% | - | - | - | - | 132.48% | 134.09% |
| Dividend per Share 2 | 34.55 | 41.82 | 41.82 | 54.55 | 54.55 | 60.00 | 66.00 | 72.50 |
| Announcement Date | 7/12/19 | 7/10/20 | 7/14/21 | 7/14/22 | 7/14/23 | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: May | 2020 S1 | 2021 S1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 S1 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 23,253 | 26,035 | 10,717 | 22,463 | 11,120 | 9,881 | 12,041 | 11,326 | 23,367 | 11,203 | 10,531 | 12,178 | 11,932 | 24,110 | 10,552 | 12,238 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | 2,829 | 3,512 | 1,517 | 3,877 | 1,769 | 907 | 1,501 | 1,325 | 2,826 | 1,280 | 1,101 | 1,080 | 1,209 | 2,289 | 816 | 1,195 |
| Operating Margin | 12.17% | 13.49% | 14.16% | 17.26% | 15.91% | 9.18% | 12.47% | 11.7% | 12.09% | 11.43% | 10.45% | 8.87% | 10.13% | 9.49% | 7.73% | 9.76% |
| Earnings before Tax (EBT) 1 | 2,963 | 3,549 | 1,454 | 4,096 | 1,813 | 811 | 1,470 | 1,235 | 2,705 | 1,291 | 1,080 | 1,092 | 1,223 | 2,315 | 1,125 | 1,178 |
| Net income 1 | 2,002 | 2,423 | 952 | 2,777 | 1,201 | 690 | 946 | 816 | 1,762 | 898 | 940 | 683 | 869 | 1,552 | 787 | 671 |
| Net margin | 8.61% | 9.31% | 8.88% | 12.36% | 10.8% | 6.98% | 7.86% | 7.2% | 7.54% | 8.02% | 8.93% | 5.61% | 7.28% | 6.44% | 7.46% | 5.48% |
| EPS | 145.0 | 162.1 | - | 183.7 | 77.96 | - | 59.74 | - | 111.3 | 56.84 | - | 43.27 | - | 98.22 | 50.13 | - |
| Dividend per Share | 18.18 | 20.91 | - | 22.73 | - | - | - | - | 27.27 | - | - | - | - | 30.00 | - | - |
| Announcement Date | 1/14/20 | 1/14/21 | 1/14/22 | 1/14/22 | 4/14/22 | 7/14/22 | 10/13/22 | 1/13/23 | 1/13/23 | 4/13/23 | 7/14/23 | 10/12/23 | 1/12/24 | 1/12/24 | 4/12/24 | - |
1JPY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: May | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 3,135 | 14 | 9.78 | - | 1,282 | 3,982 | 4,555 | 4,419 |
| Net Cash position 1 | - | - | - | 945 | - | - | - | - |
| Leverage (Debt/EBITDA) | 0.4237 x | 0.001685 x | 0.001079 x | - | 0.1412 x | 0.4856 x | 0.4433 x | 0.4063 x |
| Free Cash Flow 1 | 3,258 | 1,575 | -1,136 | - | -412 | -1,183 | 5,200 | 5,920 |
| ROE (net income / shareholders' equity) | 11.9% | 11.7% | 10.9% | 10.5% | 7.3% | 5.8% | 6.95% | 7.25% |
| ROA (Net income/ Total Assets) | 9.88% | 10.8% | 10.8% | 11% | 7.63% | 5.9% | 6.05% | 6.45% |
| Assets 1 | 35,556 | 36,464 | 39,187 | 42,552 | 47,182 | 56,610 | 64,876 | 68,450 |
| Book Value Per Share 2 | 2,248 | 2,520 | 2,759 | 3,009 | 3,207 | 3,371 | 3,751 | 4,051 |
| Cash Flow per Share | 462.0 | 492.0 | 493.0 | 521.0 | 472.0 | - | - | - |
| Capex 1 | 3,630 | 2,731 | 6,319 | 4,627 | 5,505 | 7,000 | 4,750 | 4,500 |
| Capex / Sales | 8.83% | 6.07% | 12.97% | 10.65% | 12.21% | 14.71% | 9.11% | 8.01% |
| Announcement Date | 7/12/19 | 7/10/20 | 7/14/21 | 7/14/22 | 7/14/23 | - | - | - |
1JPY in Million2JPY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2,502
JPY
Average target price
3,155
JPY
Spread / Average Target
+26.10%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +31.34% | 245M | |
| +21.30% | 43.18B | |
| +20.67% | 22.59B | |
| +14.56% | 14.56B | |
| +14.09% | 13.54B | |
| +42.34% | 11.5B | |
| -8.37% | 6.93B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +10.21% | 5.36B |
- Stock Market
- Equities
- 4577 Stock
- Financials Daito Pharmaceutical Co.,Ltd.
